FIGURE 2. 17-HDHA and AT-RvD1 vaccine adjuvants restore SHS-suppressed systemic and mucosal antigen-specific antibody levels.

(A) Mice chronically exposed to SHS or air control for 8 wks were vaccinated with P6 antigen either in the presence or absence of SPM adjuvants 17-HDHA or AT-RvD1 as described in the methods section. Sham-immunized mice were vaccinated with PBS alone. All the animals were euthanized 8 wks after the start of vaccination (at wk 16). (B-C) Vaccination efficacy was determined by measuring the total anti-P6 IgG antibody levels in serum and endpoint BAL samples by ELISA (n=10 per group). (D-F) P6-specific IgG1 and IgG2b antibody subclass levels in endpoint serum and BAL, and (G) the levels of mucosal anti-P6 IgA antibody in endpoint BAL were determined by measuring OD values at 450 nm by ELISA. All treatment groups were assayed at the same time, and data represent results generated from a single experiment using n=10 mice per treatment group. Data from individual mice are shown, the line represents geometric mean ± 95% C.I. Statistical significance was determined as described in the methods section. Overall p<0.0001 comparing SHS, P6+vehicle group vs all treatment groups with Tukey’s posttest for multiple comparisons. For Figure 2B, ****p≤0.0001 with Tukey's posttest comparison of SHS, P6+Veh versus SHS, P6+AT-RvD1 or SHS, P6+17-HDHA adjuvant groups (overall p=0.0001 comparing SHS, P6+vehicle group vs all treatment groups).